Jennifer D. Goldman, PharmD, CDE, BC-ADM, FCCP

The 2025 National Lipid Association (NLA) Scientific Sessions highlighted a strategic shift toward early, aggressive cardiometabolic intervention, underscoring the vital role of pharmacists in implementing emerging therapies and optimizing cardiovascular risk reduction.

Ninety percent of diabetes cases are type 2, which is a major cause of morbidity and mortality.